For patients initiating oral anticoagulant therapy, the incidence of hospitalization for upper gastrointestinal bleeding is highest and lowest with rivaroxaban and apixaban, respectively.
Because of various clinical situations, there may be a need for clinicians to transition patients from one anticoagulant therapy to another. In order to do this safely, the pharmacology profiles of both agents should be taken into consideration.
Janssen Pharmaceuticals announced that the FDA has approved Xarelto (rivaroxaban) tablets to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
The researchers found that the risk of developing an intraocular hemorrhage was reduced with dabigatran or rivaroxaban at 365 days (hazard ratio, 0.75; 95% confidence interval, 0.58 to 0.97; P=0.03) but not at 90 days (hazard ratio, 0.73; 95% confidence interval, 0.22 to 2.63; P=0.13).
Background- During long-term anticoagulation in atrial fibrillation, temporary interruptions (TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been well studied. Methods and Results- In the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition …
Andexxa was initially granted accelerated approval in May 2018 for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation was needed due to life-threatening or uncontrolled bleeding.
